Subcutaneous Omacetaxine Effective in Chronic- or Accelerated-Phase CML Resistant to 2 or More TKIs

Subcutaneous Omacetaxine Effective in Chronic- or Accelerated-Phase CML Resistant to 2 or More TKIs Including Imatinib

Posting Date: December 19, 2011

Post hoc analysis of 2 open-label, multicenter, single-arm, phase II studies

http://www.clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202011/Tracks/CML/Capsules/3761.aspx